Influence of rate of administration of raclopride on akathisia and prolactin response

The D₂-dopamine receptor antagonist raclopride was administered to eight healthy male subjects, who had previously experienced akathisia following antipsychotic drugs. The influence of administration rate on onset, severity and duration of akathisia and on prolactin response was studied. Raclopride 3,5 or 9 mg or placebo (P) was administered as single IV infusions during 10 min (R10 min/3 mg), 1 h (R1h/5 mg) or 4 h (R4h/9 mg) according to a randomized double-blind design. Despite a 24-fold difference in administration rate a similar peak raclopride concentration of about 350 nmol/l was obtained after all three infusions. Three of the eight subjects experienced akathisia following R10 min/3 mg and R1h/5 mg, respectively. After R4h/9 mg seven subjects experienced akathisia of longer duration but not more severe than after the short infusions. The incidence and duration of akathisia seem to be mainly related to the plasma raclopride concentrations over time, whereas the rate of administration might be more important for the severity. A maximal prolactin response was induced which was not markedly affected by the rate of administration.     

Aminoglycoside therapy Current use and future prospects

The microbiological, pharmacokinetic, toxicological and clinical aspects of aminoglycosides are reviewed. Aminoglycosides still have an important place in serious infections in neutropenic patients, endocarditis andPseudomonas aeruginosa infections, all in combination with beta-lactams. Monotherapy (with streptomycin) is indicated in less common diseases like tularaemia and bubonic plague. Several experimental studies support a oncedaily dosing regimen for aminoglycosides (comparable or better efficacy with less ototoxicity and nephrotoxicity). Only a very limited number of prospective comparative studies have been performed, and much more data on efficacy, development of resistance and toxicity is needed before once-daily administration can be recommended. The choice of an aminoglycoside should be based primarily on the local sensitivity patterns and cost. Differences in ototoxicity and nephrotoxicity are usually minor. If the acquisition costs of amikacin decline, it is to be expected that amikacin will be the aminoglycoside of choice.     

低抗凝肝素来源低分子肝素口服制剂的研究

以生产肝素的副产品——低抗凝肝素为原料,采用亚硝酸控制解聚法制得了低分子肝素,分子量为5300,抗凝活性为39.2u/mg,测定了理化指标。以对家兔实验性血栓形成的影响为药效学指标,确定低分子肝素口服制剂的处方组成为低分子肝素、油酸、牛胆盐。研究了所制备的低分子肝素胶囊对家兔血液流变学及血栓形成的影响,并试用于部分动脉粥样硬化症志愿者,表明该胶囊可有效地改善家免和动脉粥样硬化症志愿者血液流变性质,抑制血栓形成。     

Bone levels of cephradine and cefuroxime after intravenous administration in patients undergoing total hip replacement

Summary A randomised, comparative study is reported of single intravenous doses of cephradine 2 g or cefuroxime 1.5 g given as prophylactic cover for total hip replacements in 40 patients. The serum and bone levels of cephalosporin achieved were higher in the cephradine treated group in proportion to the higher dose employed. Both agents provided adequate bone levels on average, cephradine 25.34 mcg/g, cefuroxime 17.39 mcg/g, although bone penetration was more variable with cefuroxime.

---

Résumé Dans cette étude comparative randomisée, 40 patients ont reçu une dose intraveineuse unique de 2 g de céphradine ou de 1,5 g de céfuroxime en tant que couverture prophylactique d'arthroplastie totale de hanche. Les concentrations sériques et osseuses de céphalosporine ont été plus élevées dans le groupe traité par la céphradine, en rapport avec l'utilisation d'une dose plus importante. Des concentrations osseuses adéquates ont été obtenues en moyenne avec les deux produits (25,34 mcg/g avec la céphradine et 17,39 mcg/g avec le céfuroxime) bien que la pénétration osseuse ait été plus variable avec le céfuroxime.

     

高龄急性脑梗死患者阿替普酶静脉溶栓有效性、安全性及预后影响因素分析

目的 探讨高龄急性脑梗死患者接受阿替普酶静脉溶栓治疗有效性、安全性和临床预后的影响
因素。
方法 前瞻性连续纳入江苏省苏北人民医院2016年9月-2018年9月收治入院进行阿替普酶静脉溶
栓治疗的急性脑梗死患者，按照年龄将患者分为年龄≥80岁组和年龄＜80岁组。比较两组患者入院
时、溶栓24 h NIHSS评分，6个月mRS评分及死亡率，观察两组溶栓相关出血转化、症状性颅内出血及
肺部感染的发生情况。应用多因素Logistic回归分析观察所有患者静脉溶栓预后的独立影响因素。
结果 最终共纳入患者119例，男性69例（58.0%），年龄范围46～94岁，平均70.12±10.55岁，入院
NIHSS评分4～38分。其中年龄≥80岁患者29例，年龄＜80岁患者90例。静脉溶栓后，两组患者溶栓
24 h NIHSS评分较入院时均明显降低（均P＜0.05），两组治疗24 h NIHSS评分比较差异无统计学意义；
两组的出血转化、症状性颅内出血、肺部感染、6个月预后良好及死亡率比较，差异均无统计学意义。
多因素Logistic回归分析显示，入院到静脉溶栓时间、入院时NIHSS评分及肺部感染是脑梗死静脉溶
栓6个月预后的独立危险因素（P＜0.05），高龄不是影响预后的因素（P＞0.05）。
结论 高龄急性脑梗死患者静脉溶栓治疗安全有效，未增加颅内出血转化风险、死亡率及不良预
后。入院到静脉溶栓时间、入院时NIHSS评分及肺部感染是急性脑梗死患者静脉溶栓6个月预后不良
的独立危险因素。     

比较行胃镜和肠镜检查术的麻醉异同点

目的比较静脉麻醉下行胃镜和肠镜检查术病人麻醉管理要点及副反应。方法选择拟行无痛性胃镜、结肠镜检查的患者各120例,在静脉麻醉下行内镜检查。观察其间生命体征变化,比较两组病人对内镜插入的耐受性、副反应以及胃镜和肠镜麻醉管理的侧重点。结果接受胃镜检查的患者麻醉期间生命体征无显著性变化,接受肠镜检查的患者,麻醉期间部分可出现反射性心率减慢和血压下降,需予以对症处理。两组病人对插入胃、肠镜的刺激耐受性良好。结论成功的静脉麻醉虽可达到无痛目的,但应注重对病人呼吸和循环功能监测,确保麻醉安全。     

SARS患者护理管理与相关因素探讨

探讨门诊护理管理者在大型综合医院应对突发疫情时的管理方法。建立新科室新体制与实施新制度新流程；建立健全消毒、隔离和防护管理制度；严格执行各项制度及工作流程；建立对各类工作人员的全员全面岗前培训考核制度；护理人员的统一协调；明确人员属地管理原则。经过采取上述一系列协调管理措施，使在门诊隔离病房、发热门诊和SARS专用手术室工作的各类人员无一人发生感染。对防止SARS向院内传播起到了重要的作用。     

静脉用丙种球蛋白治疗新生儿重症感染对细胞免疫功能的影响

应用静脉注丙球(IVIG),配合抗生素(An)治疗重症感染新生儿12例,在观察疗效及不良反应的同时,通过检测患儿治疗前后T细胞亚群及白细胞介素Ⅱ(IL-2)产生水平的变化,观察IVIG对细胞免疫功能的影响。结果显示:患儿CD_3~+、CD_4~+、CD_8~+细胞及IL-2产生水平均明显低于正常同龄新生儿。经IVIG+An及单用An治疗后,T细胞各亚群及IL-2水平均明显增高。IVIG组与An组比较,诒疗后IVIG组CD_4~+细胞明显高于An组,IL-2水平也较An组为高,但无统计学意义。疗效观察,中毒症状及原发病体征好转消失时间IVIG组较An组明显缩短。本文还就IVIG对细胞免疫功能影响的可能机制进行了讨论。     

Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation

In two independent trials 10 and 12 healthy volunteers received the novel intravenous immunoglobulin (IVIG) preparations BT 511 and BT 507, respectively. BT 511 contains 5 g human plasma proteins per 100 ml, more than 95% of which are immunoglobulins of the G class (IgG). BT 507 contains in addition 61 IU antibody against hepatitis B surface antigen (anti-HBs)·ml^–1. In trial I volunteers received 4.0 ml/kg (n+4) and 8.0 ml·kg^–1 (n+6) BT 511 to study the tolerability and the magnitude of the increase in immunoglobulins in plasma as well as their decline over 1 month. After administration of the lower dose, plasma IgG increased from 10.7 to 14.7 g·l^–1 directly after the infusion. Following the 8.0 ml·kg^–1 dose a more pronounced increase from 12.4 to 21.2 g·l^–1 was observed. No adverse events occurred. After 1 month IgG concentrations had almost reached baseline values at 12.2 g·l^–1 in the 4.0 ml·kg^–1 group, but were still significantly increased at 15.2 g·l^–1 after the high dose. There was a linear correlation between the maximal IgG plasma concentration and the subsequent decline of IgG during the 29-day observation period. After administration of BT 507 maximal anti-HBs concentrations of 1778 mU·ml^–1 occurred 1.4 h after termination of the infusion. The terminal elimination half-life was 22.4 days, and total clearance and volume of distribution were determined to be 0.122 ml·min^–1 and 5.41, respectively. The pharmacokinetic parameters calculated for anti-HBs as an indicator of IgG were in accordance with the pharmacokinetic behaviour of native IgG.     

SARS一线护士的健康调查及防治对策的探讨

目的 调查从事SARS一线护理工作的护士健康状况，为制定合理的卫生保健措施提供可借鉴的建议。方法 对一线工作人员不同时间点的各项生理指标进行观测，并根据结果采取针对措施。结果 一线工作护士各项生理指标均较正常时出现明显波动，采取相应措施后有明显改善。结论 良好的防治措施对改善一线护士的健康状况大有裨益。